Cargando…

Achieving and sustaining herd immunity to SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Bolotin, Shelly, Wilson, Sarah, Murti, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Joule Inc. 2021
Materias:	Practice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315197/ https://www.ncbi.nlm.nih.gov/pubmed/34281966 http://dx.doi.org/10.1503/cmaj.210892

Ejemplares similares

Atteinte et maintien de l’immunité collective contre le SRAS-CoV-2
por: Bolotin, Shelly, et al.
Publicado: (2021)

Contact-adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity
por: Chun, June Young, et al.
Publicado: (2021)

SARS-CoV-2: from herd immunity to hybrid immunity
por: Goldblatt, David
Publicado: (2022)

SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
por: Kouamou, Vinie, et al.
Publicado: (2021)

How Long that a SARS-CoV-2 Variant Delay Impacts Required Period to Achieve Herd Immunity?
por: Joob, Beuy, et al.
Publicado: (2023)

SARS-CoV-2 vaccination in pregnancy
por: Dalcin, Daniel, et al.
Publicado: (2023)

Shoulder injury related to SARS-CoV-2 vaccine administration
por: Chow, Jacky C.K., et al.
Publicado: (2022)

Developing sustainable workflows for community pharmacy–based SARS-CoV-2 testing
por: O’Connor, Shanna K., et al.
Publicado: (2022)

Rapid antigen tests for SARS-CoV-2
por: Liu, Michael, et al.
Publicado: (2021)

Cross-reactive memory T cells and herd immunity to SARS-CoV-2
por: Lipsitch, Marc, et al.
Publicado: (2020)

Is Herd Immunity Against SARS-CoV-2 a Silver Lining?
por: Vignesh, Ramachandran, et al.
Publicado: (2020)

Herd immunity threshold for SARS-CoV-2 and vaccination effectiveness in Brazil
por: Siqueira, Priscila C., et al.
Publicado: (2022)

Attack rate and the price of SARS-CoV-2 herd immunity in Brazil
por: Filho, Tarcisio Rocha, et al.
Publicado: (2021)

NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection
por: Vohra-Miller, Sabina, et al.
Publicado: (2022)

Urticaria and angioedema associated with SARS-CoV-2 infection
por: Zipursky, Jonathan S., et al.
Publicado: (2021)

Palatal mucormycosis in a patient with SARS-CoV-2 infection
por: Venugopal, Adith, et al.
Publicado: (2021)

Functional neurologic disorder associated with SARS-CoV-2 vaccination
por: Zhu, Annie, et al.
Publicado: (2022)

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
por: Anderson, Roy M, et al.
Publicado: (2020)

Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão
por: da Silva, Antônio Augusto Moura, et al.
Publicado: (2020)

SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar
por: Al-Thani, Mohamed H, et al.
Publicado: (2021)

Immediate reactions after mRNA SARS-CoV-2 vaccination
por: Jeimy, Samira, et al.
Publicado: (2021)

Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection
por: Kerkerian, Geneviève, et al.
Publicado: (2021)

Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold
por: Gomes, M. Gabriela M., et al.
Publicado: (2022)

Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold
por: Gomes, M. Gabriela M., et al.
Publicado: (2022)

Seroprevalence and attainment of herd immunity against SARS CoV-2: A modelling study
por: Paul, Abhijit, et al.
Publicado: (2021)

SARS-CoV-2: big seroprevalence data from Pakistan—is herd immunity at hand?
por: Haq, Mohsina, et al.
Publicado: (2021)

Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2
por: Plans-Rubió, Pedro
Publicado: (2022)

Persistent myopericarditis after heterologous SARS-CoV-2 mRNA vaccination
por: Wu, Kai Yi, et al.
Publicado: (2023)

Rapid Diagnostic Testing for SARS-CoV-2
por: Drain, Paul K.
Publicado: (2022)

Adverse cutaneous reactions after mRNA SARS-CoV-2 vaccination in 3 patients: a spectrum of severity
por: Edgerley, Sarah, et al.
Publicado: (2022)

Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects
por: Bicher, Martin, et al.
Publicado: (2022)

Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review
por: Perry, Julie, et al.
Publicado: (2022)

A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2
por: Britton, Tom, et al.
Publicado: (2020)

High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!
por: Núñez-Zapata, Susy Fanny, et al.
Publicado: (2021)

Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity
por: Pacheco-García, Ursino, et al.
Publicado: (2023)

Bacillus Calmette–Guérin scar flare after an mRNA SARS-CoV-2 vaccine
por: Lim, Darren Wan-Teck, et al.
Publicado: (2021)

Severe myocarditis after SARS-CoV-2 vaccination in a 49-year-old woman
por: Olmos, Carla Vallejos, et al.
Publicado: (2022)

Erythema multiforme major associated with SARS-CoV-2 infection in a patient with skin of colour
por: Pourghadiri, Amir, et al.
Publicado: (2023)

SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
por: Bolotin, Shelly, et al.
Publicado: (2021)

Can Africa achieve herd immunity?
por: Lucero-Prisno, Don Eliseo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tnprc8rkk7us528hgntgiu7s8p